NO972558L - Set for osteoporosis treatment cycle - Google Patents

Set for osteoporosis treatment cycle

Info

Publication number
NO972558L
NO972558L NO972558A NO972558A NO972558L NO 972558 L NO972558 L NO 972558L NO 972558 A NO972558 A NO 972558A NO 972558 A NO972558 A NO 972558A NO 972558 L NO972558 L NO 972558L
Authority
NO
Norway
Prior art keywords
treatment cycle
osteoporosis treatment
osteoporosis
solvate
kit
Prior art date
Application number
NO972558A
Other languages
Norwegian (no)
Other versions
NO972558D0 (en
Inventor
Martine Gazard
Olivier Gros
Jacques Girard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO972558D0 publication Critical patent/NO972558D0/en
Publication of NO972558L publication Critical patent/NO972558L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives et sett for anvendelse i en terapeutisk syklus basert på sekvensiell tilførsel av tiludronsyre eller av et salt og/eller solvat av denne, og av kalsium i 28 til 31 dager, for behandling og/eller forebygging av osteoporose.A kit is described for use in a therapeutic cycle based on the sequential application of tiludronic acid or a salt and / or solvate thereof, and of calcium for 28 to 31 days, for the treatment and / or prevention of osteoporosis.

NO972558A 1994-12-06 1997-06-05 Set for osteoporosis treatment cycle NO972558L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9414630A FR2727629A1 (en) 1994-12-06 1994-12-06 OSTEOPOROSIS TREATMENT CYCLE KIT
PCT/FR1995/001596 WO1996017616A1 (en) 1994-12-06 1995-12-05 Kit for osteoporosis treatment cycle

Publications (2)

Publication Number Publication Date
NO972558D0 NO972558D0 (en) 1997-06-05
NO972558L true NO972558L (en) 1997-08-05

Family

ID=9469504

Family Applications (1)

Application Number Title Priority Date Filing Date
NO972558A NO972558L (en) 1994-12-06 1997-06-05 Set for osteoporosis treatment cycle

Country Status (20)

Country Link
EP (1) EP0797444A1 (en)
JP (1) JPH10509729A (en)
KR (1) KR980700083A (en)
CN (1) CN1168634A (en)
AR (1) AR002946A1 (en)
AU (1) AU4307396A (en)
BR (1) BR9509961A (en)
CA (1) CA2207028A1 (en)
CZ (1) CZ175397A3 (en)
FI (1) FI972383A0 (en)
FR (1) FR2727629A1 (en)
HU (1) HUT77382A (en)
IL (1) IL116168A0 (en)
MA (1) MA23737A1 (en)
NO (1) NO972558L (en)
PL (1) PL320564A1 (en)
SK (1) SK68597A3 (en)
TR (1) TR199501530A1 (en)
WO (1) WO1996017616A1 (en)
ZA (1) ZA9510184B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
ES2532393T3 (en) 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Bisphosphonic acids for treatment and prevention of osteoporosis
DE60315514T3 (en) * 2002-12-20 2012-04-26 F. Hoffmann-La Roche Ag HIGH-DOSED IBANDRONATE FORMULATION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3583887D1 (en) * 1984-04-30 1991-10-02 Procter & Gamble EQUIPMENT FOR TREATING OSTEOPOROSIS.
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE69316013T2 (en) * 1992-06-30 1998-07-09 Procter & Gamble Pharma USE OF PHOSPHINATE FOR TREATING OSTEOPOROSIS
FR2694558B1 (en) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate of the disodium salt of 4-chlorophenylthiomethylene bisphosphonic acid, its preparation, the pharmaceutical compositions containing it.

Also Published As

Publication number Publication date
CZ175397A3 (en) 1997-10-15
NO972558D0 (en) 1997-06-05
BR9509961A (en) 1997-11-25
JPH10509729A (en) 1998-09-22
PL320564A1 (en) 1997-10-13
FR2727629B1 (en) 1997-02-28
AR002946A1 (en) 1998-05-27
HUT77382A (en) 1998-04-28
CA2207028A1 (en) 1996-06-13
IL116168A0 (en) 1996-01-31
SK68597A3 (en) 1997-11-05
MX9704105A (en) 1997-09-30
AU4307396A (en) 1996-06-26
ZA9510184B (en) 1996-06-11
EP0797444A1 (en) 1997-10-01
MA23737A1 (en) 1996-07-01
CN1168634A (en) 1997-12-24
TR199501530A1 (en) 1996-10-21
KR980700083A (en) 1998-03-30
WO1996017616A1 (en) 1996-06-13
FI972383A (en) 1997-06-05
FI972383A0 (en) 1997-06-05
FR2727629A1 (en) 1996-06-07

Similar Documents

Publication Publication Date Title
DE122006000010I2 (en) Benzocyclobutyl or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones, useful in the treatment of cardiovascular diseases
IS4083A (en) Composition of pharmaceutical substances, method of manufacture thereof, and use as pharmaceuticals
DE69721766D1 (en) NEW MEDICAL FORMULATION
DE3463442D1 (en) Arched bridge staple
NO307408B1 (en) Amino sugars and glycosaminoglyc composition for the treatment and repair of connective tissue
EP0209689A3 (en) Use of tetrahydrobiopterins in the treatment of infantile autism
NO20061455L (en) 2.6 dioxopiperidine and pharmaceutical preparations containing them
DK0480934T3 (en) Drug containing ephedrine and caffeine for the treatment of obesity
PT705100E (en) THERAPEUTIC SUBSTITUTED GUANIDINS
DK549189A (en) GALANTHAMINE ANALOGUE AND USE OF THESE FOR THE PREPARATION OF MEDICINALS FOR TREATMENT OF ALZHEIMER'S DISEASE
TW360544B (en) Analgestic and antiinflammatory fomentation pharmaceutical composition
DE3578611D1 (en) INSTRUMENTS FOR TREATING DEFORMED NAILS IN HUMAN PATIENTS.
NO305581B1 (en) Use of a bone active phosphonate in combination with a ° hormone, and unit dosage form for the treatment of osteoporosis
ATE203907T1 (en) DERMATOLOGICAL PREPARATION FOR THE TREATMENT OF ACTINIC KERATOSIS
DE69316013D1 (en) USE OF PHOSPHINATE FOR TREATING OSTEOPOROSIS
ATE131060T1 (en) CHENODEOXYCHOLIC ACID OR URSODEOXYCHOLIC ACID FOR TREATING DISEASES OF THE RESPIRATORY ORGANS.
NO972558L (en) Set for osteoporosis treatment cycle
NO155375C (en) NATURAL TISSUE SUITABLE FOR IMPLEMENTATION IN A LIVING BODY AND PROCEDURE TO AA REDUCE THE CALCULATION OF NATURAL TISSUE LOCATED AFTER IMPLEMENTATION IN A LIVING BODY
NZ326345A (en) Composition containing diosgenin
DK325289A (en) STRONTIUM SALT, METHOD OF PREPARING IT, AND PHARMACEUTICAL AGENTS CONTAINING SALT
DE69218200T2 (en) TREATMENT OF LIVER CANCER
DK0583281T3 (en) Antidote - immune sera
SE8501202D0 (en) HUMAN INTESTINAL HORMONE AND ITS USE
NO960347L (en) Use of benzydamide in the treatment of pathological conditions caused by TNF
KR960700729A (en) Use of 26,26,26,27,27,27-hexafluoro-1 alpha, 25-dihydroxycholecalciferol for the treatment of calcium metabolic disorders (Use of 26,26,26,27,27,27- Hexafluoro-1alpha, 25-Dihydroxycholecalciferol for the treatment of Calcium Metabolism Disorders)